Business Description
Replimune Group Inc
NAICS : 325412
SIC : 2834
ISIN : US76029N1063
Compare
Compare
Traded in other countries / regions
REPL.USA7R8.Germany Index Membership
Russell 2000Russell 3000 IPO Date
2018-07-20Description
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 6.35 | |||||
| Equity-to-Asset | 0.75 | |||||
| Debt-to-Equity | 0.18 | |||||
| Debt-to-EBITDA | -0.32 | |||||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -10.3 | |||||
| 3-Year EPS without NRI Growth Rate | -13.1 | |||||
| 3-Year FCF Growth Rate | -15.1 | |||||
| 3-Year Book Growth Rate | -14.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 28.33 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 30.14 | |||||
| 9-Day RSI | 41.29 | |||||
| 14-Day RSI | 46.77 | |||||
| 3-1 Month Momentum % | 6.9 | |||||
| 6-1 Month Momentum % | -25.85 | |||||
| 12-1 Month Momentum % | -4.06 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.95 | |||||
| Quick Ratio | 7.95 | |||||
| Cash Ratio | 7.76 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -17.6 | |||||
| Shareholder Yield % | -22.63 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -59.43 | |||||
| ROA % | -46.21 | |||||
| ROIC % | -336.55 | |||||
| 3-Year ROIIC % | -813.74 | |||||
| ROC (Joel Greenblatt) % | -453.24 | |||||
| ROCE % | -48.85 | |||||
| Moat score | 5 | |||||
| Tariff score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.77 | |||||
| Price-to-Tangible-Book | 1.77 | |||||
| EV-to-EBIT | -1.25 | |||||
| EV-to-EBITDA | -1.26 | |||||
| EV-to-Forward-Revenue | 3.38 | |||||
| EV-to-FCF | -1.5 | |||||
| Price-to-Net-Current-Asset-Value | 2.04 | |||||
| Price-to-Net-Cash | 2.11 | |||||
| Earnings Yield (Greenblatt) % | -80 | |||||
| FCF Yield % | -27.02 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers